UPDATE : Wednesday, June 19, 2019
HOME Pharma
Kwangdong licenses Canadian company’s nonsteroidal anti-inflammatory drug candidate
  • By Lee Han-soo
  • Published 2018.09.10 14:23
  • Updated 2018.09.10 14:23
  • comments 0

Kwangdong Pharmaceutical said Monday that it has signed a licensing agreement with Antibe Therapeutics, a Canadian pharmaceutical company, to gain exclusive domestic rights for ATB-346, a nonsteroidal anti-inflammatory drug candidate.

ATB-346 is a drug that improves the pain associated with rheumatoid arthritis and osteoarthritis. The treatment also enhances gastrointestinal disturbance, a side effect of the existing non-steroidal anti-inflammatory analgesic. Antibe Therapeutics is planning to proceed with phase 3 clinical trials and apply for a new drug application (NDA) to the U.S. Food and Drug Administration (FDA).

"As a result of recent clinical trials in Canada, ATB-346 has proved that it causes almost no gastrointestinal disturbances compared to conventional drugs," Antibe Therapeutics official said.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top